Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of cytotoxicity of pegylated liposomal recombinant human erythropoietin-alfa on neuroblastoma cell line SH-SY5Y

Samaneh Shahbaz Hoseineh¹, Azim Akbarzadeh² , Hossein Attar¹

¹Department of Chemical Engineering, Science and Research Branch, Islamic Azad University; ²Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran.

For correspondence:- Azim Akbarzadeh Email: azimakbarzadeh1326@gmail.com Tel:+989128387017

Received: 18 March 2015 Accepted: 18 May 2015 Published: 29 June 2015

Citation: Hoseineh SS, Akbarzadeh A, Attar H. Effect of cytotoxicity of pegylated liposomal recombinant human erythropoietin-alfa on neuroblastoma cell line SH-SY5Y. Trop J Pharm Res 2015; 14(6):977-981 doi: 10.4314/tjpr.v14i6.6

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the cytotoxic effect of pegylated liposomal Recombinant Human Erythropoietin-alfa (rHuEPO) nanoparticles synthesized by reverse phase evaporation technique on SH-SY5Y cell line.

Methods: To prepare the nanoparticles of the drug, rHuEPO, PEG3000, cholesterol and phosphatidylcholine were dissolved in buffer phosphate. The characteristics of the synthesized nanoparticles were determined by a zetasizer. Encapsulation efficiency, drug loading efficiency and drug release pattern were evaluated spectrophotometrically. The cytotoxicity effect of pegylated nanoliposomal rHuEPO was evaluated on SH-SY5Y cell line by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

Results: Size and zeta potential of pegylated nanoliposomal drug and blank pegylated nanoliposomes were 571 ± 6.8 nm, -16.5 mV; 280 ± 4.71 nm and -27.1 mV, respectively. Encapsulation and drug loading efficiency were 89 ± 3.9 % and 0.8 ± 0.012 %, respectively. Drug release data indicate that 17 % of rHuEPO was released from pegylated liposomal nanoparticles over a period of 30 h. The difference in cytotoxicity between the free drug (IC₅₀ = 110.1 ± 3.1 µg/ml) and nanodrug (IC₅₀ = 87.2 ± 2.3 µg/ml) was statistically significant (p F6; 0.05).

Conclusion: This study shows that pegylated nanoliposomal rHuEPO has a powerful cytotoxic effect on SH-SY5Y cell line and is therefore a suitable alternative to the standard therapy, rHuEPO, for the chemotherapy of neuroblastoma.

Keywords: Recombinant Human Erythropoietin-alfa, Cytotoxicity, Drug delivery, Liposome, Reverse phase evaporation, SH-SY5Y cell line